A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
Brazilian Journal of Infectious Diseases
Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIVpositive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replicationdoi:10.1016/s1413-8670(11)70237-9 pmid:22230862 fatcat:rfzsjgjnezbbxczkoroezidhme